Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy PDL BioPharma stock

Own PDL BioPharma stock in just a few minutes.

PDL BioPharma, Inc is a biotechnology business based in the US. PDL BioPharma shares (PDLI) are listed on the NASDAQ and all prices are listed in US Dollars. PDL BioPharma employs 109 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in PDL BioPharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PDLI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

PDL BioPharma share price

Use our graph to track the performance of PDLI stocks over time.

PDL BioPharma shares at a glance

Information last updated 2021-04-18.
52-week range$2.09 - $3.78
50-day moving average $2.58
200-day moving average $2.80
Wall St. target price$2.50
PE ratio 476.6667
Dividend yield N/A (0%)
Earnings per share (TTM) $0.01

Buy PDL BioPharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy PDL BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is PDL BioPharma under- or over-valued?

Valuing PDL BioPharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PDL BioPharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

PDL BioPharma's P/E ratio

PDL BioPharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 477x. In other words, PDL BioPharma shares trade at around 477x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

PDL BioPharma's PEG ratio

PDL BioPharma's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PDL BioPharma's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

PDL BioPharma financials

Revenue TTM $27.8 million
Gross profit TTM $13.4 million
Return on assets TTM -4.1%
Return on equity TTM -7.36%
Profit margin 0%
Book value $3.69
Market capitalisation $282.1 million

TTM: trailing 12 months

Shorting PDL BioPharma shares

There are currently 11.9 million PDL BioPharma shares held short by investors – that's known as PDL BioPharma's "short interest". This figure is 0.4% up from 11.8 million last month.

There are a few different ways that this level of interest in shorting PDL BioPharma shares can be evaluated.

PDL BioPharma's "short interest ratio" (SIR)

PDL BioPharma's "short interest ratio" (SIR) is the quantity of PDL BioPharma shares currently shorted divided by the average quantity of PDL BioPharma shares traded daily (recently around 2.3 million). PDL BioPharma's SIR currently stands at 5.2. In other words for every 100,000 PDL BioPharma shares traded daily on the market, roughly 5200 shares are currently held short.

However PDL BioPharma's short interest can also be evaluated against the total number of PDL BioPharma shares, or, against the total number of tradable PDL BioPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PDL BioPharma's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 PDL BioPharma shares in existence, roughly 100 shares are currently held short) or 0.1075% of the tradable shares (for every 100,000 tradable PDL BioPharma shares, roughly 108 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against PDL BioPharma.

Find out more about how you can short PDL BioPharma stock.

PDL BioPharma share dividends

We're not expecting PDL BioPharma to pay a dividend over the next 12 months.

Have PDL BioPharma's shares ever split?

PDL BioPharma's shares were split on a 2:1 basis on 9 October 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your PDL BioPharma shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for PDL BioPharma shares which in turn could have impacted PDL BioPharma's share price.

PDL BioPharma share price volatility

Over the last 12 months, PDL BioPharma's shares have ranged in value from as little as $2.09 up to $3.78. A popular way to gauge a stock's volatility is its "beta".

PDLI.US volatility(beta: 1.14)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PDL BioPharma's is 1.1407. This would suggest that PDL BioPharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

PDL BioPharma overview

PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site